With the aim of obtaining more powerful inhibitors capable not only of modulating the immune response, but of promoting the differentiation and proliferation of neuronal cells, the synthesis of multi-target compounds for GSK3β and PDE7 was proposed for the treatment of neurodegenerative and demyelinating diseases [20]. Here, PDE7A is linked to demyelinating disease.